Skip to contentP
Panacea Life Sciences Holdings, Inc.
P
PLSHPanacea Life Sciences Holdings, Inc. Q3 2020 · 10-Q
Revenue$1.34M$1.34M+2,133.7% vs Q3 2019 Net Income-$3.78M-$3.78MN/M vs Q3 2019 EPS Diluted-$0.22-$0.22N/M vs Q3 2019 Gross Profit-$1,562,139N/M Operating Income
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Panacea Life Sciences Holdings, Inc. · CIK 1552189 · Engraved from SEC EDGAR
Operating Cash Flowderived-$600,347N/M Free Cash Flowderived-$3,901,874N/M Margins · derivedGross margin-116.3%−49.3 pt vs Q3 2019
Operating margin-249.2%+3110.0 pt vs Q3 2019
Net margin-281.3%+3086.4 pt vs Q3 2019
ended Sep 30, 2020 · filed Nov 18, 2020 · 49 d after period end